Aerosols

Encore Healthcare Announces Staggering Results in New Nexus TeleRespiratory Care Pilot Using Data to Predict when Oxygen/Nebulizer Patients Need Non-Invasive Ventilation (NIV) Before Hospitalizations Happen

Friday, June 11, 2021 - 1:32pm

LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.

Key Points: 
  • LIVINGSTON, Tenn., June 11, 2021 /PRNewswire/ --Encore Healthcare announces staggering results from their new oxygen and nebulizer management Nexus TeleRespiratory Care model.
  • In the initial pilot with a national HME provider Encore identified 12.5% of patients on oxygen/nebulizers needed additional services including medications, NIV and High Frequency Chest Wall Oscillation (HFCWO).
  • These results are an example of how data can drive better patient outcomes and revenue to HME providers at the same time.
  • The Nexus platform aligns HME respiratory providers across traditional boundaries while increasing provider productivity and clinical outcomes with their Ventilator/High-Risk COPD patients.

$12.2 Billion Aerosol Cans Market by Material, Product Type, End-use Sector - Global Forecast to 2026 with Focus on Personal Care, Healthcare, Household Care, Automotive - ResearchAndMarkets.com

Monday, May 24, 2021 - 5:49pm

Aerosol cans are used in various end-use sectors such as personal care, household care, healthcare, automotive, and others.

Key Points: 
  • Aerosol cans are used in various end-use sectors such as personal care, household care, healthcare, automotive, and others.
  • Aluminum material segment accounted for the largest share in the global aerosol cans market during the forecast period.
  • 1 piece aerosol cans product type segment accounted for the largest share in the global aerosol cans market during the forecast period.
  • The personal care end-use sector segment accounted for the largest share in the global aerosol cans market during the forecast period.

In Utero Exposure to Tiny Pollution Particles in the Air Is Linked to Asthma in Preschoolers, Study Shows

Friday, May 21, 2021 - 10:35pm

These have been associated with asthma risk in children in prior research.

Key Points: 
  • These have been associated with asthma risk in children in prior research.
  • Because of this, the researchers said their toxic effects may actually be greater.\n"One reason ultra-fine particulates are not routinely monitored is that there have been a number of unique challenges to measuring them accurately.
  • Most of the diagnoses of asthma occurred just after three years of age.\nPollution\'s effect in utero can alter lung development and respiratory health.
  • As we advance methods for measuring these tiny particles, we hope for replication of these findings, both within different geographic areas across the United States as well as globally.

Rustic MAKA Introduces World's First-of-Its-Kind 2-in-1 Duo Scent Deodorant for a Unique, Amazingly Refreshing Experience

Friday, May 21, 2021 - 10:12pm

These are not your average deodorants, as both DEO DUO sticks are layered with two unique scents in one container, meaning you will never get bored again.

Key Points: 
  • These are not your average deodorants, as both DEO DUO sticks are layered with two unique scents in one container, meaning you will never get bored again.
  • No other body care brand has layered scents like this ever before.
  • Theyembrace simplicity and offer products that go beyond today's standards of natural, through use of exceptional ingredients and no animal testing.
  • Rustic MAKAbelieves in simple ingredients transformed into effective and good-for-the-body products that actually work.\nIf you would like more information, please contact:\n"

Grove Collaborative Expands Peach Personal Care Line with First-Ever 100% Plastic-Free Deodorant & Body Care Refill System

Tuesday, May 18, 2021 - 1:46pm

b'Grove Collaborative, the leading sustainable consumer products company that creates innovative natural products and offers a curated selection of healthy home essentials and personal care products, announces the expansion of its personal care line, Peach, with the launch of the first-ever 100% plastic-free Deodorant & Body Care refill system.

Key Points: 
  • b'Grove Collaborative, the leading sustainable consumer products company that creates innovative natural products and offers a curated selection of healthy home essentials and personal care products, announces the expansion of its personal care line, Peach, with the launch of the first-ever 100% plastic-free Deodorant & Body Care refill system.
  • While niche brands and big industry players have introduced deodorant refills, the options in the market currently all have plastic components.
  • \xe2\x80\x9cThe Peach deodorant and lotion line builds on Grove\xe2\x80\x99s leadership in sustainable packaging and is the industry\xe2\x80\x99s first-ever 100% plastic-free Deodorant and Body Care refill system.
  • Now, with the launch of the first-ever 100% plastic-free Deodorant & Body Care refill system, Peach is continuing its mission by expanding its domain beyond the shower and into the bathroom cabinet.\nThe Peach Deodorant and Body Care refill system comes in plastic-free, refillable deodorant, body lotion and body balm stick formats that utilize clean and vegan formulas with 100% natural fragrances.

Global Nebulizers (Pneumatic, Ultrasonic, Mesh) Market Report 2021: COVID-19 Impacts, Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Wednesday, May 12, 2021 - 1:32pm

b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.

Key Points: 
  • b'The "Nebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nNebulizers Global Market Report 2021: COVID-19 Implications and Growth to 2030 covers this critical market and the impact on it from the COVID-19 virus.
  • The market is expected to reach $1.55 billion in 2025 at a CAGR of 10.5%.\nThe nebulizer devices market consists of sales of nebulizers used in respiratory care for patients with respiratory diseases including asthma, cystic fibrosis and COPD.
  • There has been an increased use of albuterol inhalers in hospitals for Covid-19 and suspected Covid-19 patients to help with respiratory issues.
  • Rise in geriatric population is anticipated to propel the nebulizer market growth.\n'

Verona Pharma to Present Expanded Analysis of Phase 2b COPD Data with Ensifentrine at the American Thoracic Society 2021 International Conference

Tuesday, May 4, 2021 - 7:00am

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (\xe2\x80\x9cCFTR\xe2\x80\x9d), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\xe2\x80\x9cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\xe2\x80\x9d) for COPD maintenance treatment.
  • Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (\xe2\x80\x9cDPI\xe2\x80\x9d) and pressurized metered-dose inhaler (\xe2\x80\x9cpMDI\xe2\x80\x9d).
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.\n"

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

Tuesday, May 4, 2021 - 3:00am

b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).

Key Points: 
  • b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).
  • Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically optimized for CSL Behring\'s formulation.
  • HCmed will receive an upfront payment and device and development milestones.
  • "\nFounded in 2014, HCmed Innovations Co., Ltd. focuses on the development of drug-device combination products based on its vibrating mesh nebulizer technology.

HCmed Signs a Global Development Agreement with Global Biotechnology Leader CSL Behring

Tuesday, May 4, 2021 - 3:00am

b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).

Key Points: 
  • b'TAIPEI, May 3, 2021 /PRNewswire/ -- HCmed today announces the start of a strategic partnership with global biotherapeutics leader CSL Behring to collaboratively develop CSL Behring\'s plasma derived immunoglobulin administered via HCmed\'s new generation vibrating-mesh nebulizing device (CSL787).
  • Under the terms of the agreement, CSL Behring will have sole responsibility for the development and commercialization of the combination product, with HCmed leading the development of the customized nebulizing device specifically optimized for CSL Behring\'s formulation.
  • HCmed will receive an upfront payment and device and development milestones.
  • "\nFounded in 2014, HCmed Innovations Co., Ltd. focuses on the development of drug-device combination products based on its vibrating mesh nebulizer technology.

DOVE® Dental Products Releases AERO 22mm Wide Mouth HVE, a Single-Use Aerosol Collection Device to Improve Patient Safety

Thursday, April 29, 2021 - 7:37pm

b'CHESTERFIELD, Mo., April 29, 2021 /PRNewswire/ --DOVE Dental Products announces the release of the new AERO HVE Wide Mouth a single-use hybrid device designed to significantly reduce the risk of airborne aerosol movement caused by instrument use in a dental setting.\nThe AERO lineup now offers two innovative dental aerosol evacuation solutions that allow for maximum suction and aerosol collection without compromising patient comfort or professional workflow.

Key Points: 
  • b'CHESTERFIELD, Mo., April 29, 2021 /PRNewswire/ --DOVE Dental Products announces the release of the new AERO HVE Wide Mouth a single-use hybrid device designed to significantly reduce the risk of airborne aerosol movement caused by instrument use in a dental setting.\nThe AERO lineup now offers two innovative dental aerosol evacuation solutions that allow for maximum suction and aerosol collection without compromising patient comfort or professional workflow.
  • In May 2020, DOVE introduced the AERO HVE Saliva Ejector, a device that combines high-volume evacuation to capture aerosols with a saliva ejector to capture liquids.
  • "\nAbout DOVE Dental Products: DOVE Dental Products is dedicated to developing and distributing innovative, cost-effective disposable oral evacuation devices that prevent backflow and eliminate cross-contamination between patients.
  • DOVE products are simple to install and intuitive with performance with no need for sterilization or autoclaving.